首页产品供求市场行情现货直销公司信息
产品
产品 公司 求购 资讯 法规
English
  1. 您当前位置：
  2. 首页
  3. 产品数据
  4. 卓那比醇

卓那比醇

  • 基本信息
  • 物化性质
  • 安全信息
  • 毒理性
  • MSDS
  • 结构与计算化学
  • 上游产品
  • 下游产品

卓那比醇 基本信息

中文名称：
卓那比醇 
中文别名：
Δ9-四氢大麻酚;
Δ1-Tetrahydrocannabinol;
9-四氢大麻酚 
英文名称：
DELTA9-TETRAHYDROCANNABINOL
英文别名：
Δ9-tetrahydrocannabinol;
THC;
Marinol;
THC ELISA;
DELTA9-TETRAHYDROCANNABINOL;
Hashish;
Delta(9)-tetrahydrocannabinol;
Ganja;
EXO-THC;
Deltanyne;
SP 104 
CAS No.：
1972-08-3
分 子 式：
C21H30O2
分 子 量：
314.46
精确分子量：
314.22500
PSA：
29.46000
MDL：
MFCD00083207
EINECS：
200-578-6
InChI：
The Key: CYQFCXCEBYINGO-SJORKVTESA-N
风险术语：
11
分子结构式：
SDS：
查看

卓那比醇 物化性质

蒸汽压：
1.18E-06mmHg at 25°C

卓那比醇 安全信息

危险类别码：
11
安全说明：
7-16
安全标志：
S7:保持容器紧密封闭。
S16:远离火源。

卓那比醇 毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :
HP8225000
CHEMICAL NAME :
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-3-pentyl-6,6,9-trimethyl- (6ar-trans)-
CAS REGISTRY NUMBER :
1972-08-3
LAST UPDATED :
199803
DATA ITEMS CITED :
94
MOLECULAR FORMULA :
C21-H30-O2
MOLECULAR WEIGHT :
314.51
WISWESSER LINE NOTATION :
T B666 HO MU&TTJ CQ E5 I1 I1 M1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
666 mg/kg
TOXIC EFFECTS :
Behavioral - tremor Behavioral - excitement Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
373 mg/kg
TOXIC EFFECTS :
Behavioral - tremor Behavioral - excitement Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
29 mg/kg
TOXIC EFFECTS :
Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression Behavioral - excitement
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
482 mg/kg
TOXIC EFFECTS :
Behavioral - tremor Behavioral - excitement Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
168 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - analgesia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>11 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
42 mg/kg
TOXIC EFFECTS :
Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression Behavioral - excitement
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
525 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - muscle contraction or spasticity Gastrointestinal - nausea or vomiting
TYPE OF TEST :
LD - Lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
>3150 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
125 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
3250 mg/kg/13W-I
TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - changes in uterine weight
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
29750 mg/kg/17W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - urine volume increased Endocrine - changes in adrenal weight Related to Chronic Data - changes in prostate weight
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1400 mg/kg/28D-I
TOXIC EFFECTS :
Brain and Coverings - other degenerative changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - true cholinesterase Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - monoamine oxidase
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9 gm/kg/26W-I
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - true cholinesterase Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
900 mg/kg/30D-I
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - changes in lung weight Liver - changes in liver weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
210 mg/kg/21D-I
TOXIC EFFECTS :
Liver - other changes Biochemical - Metabolism (Intermediary) - lipids including transport
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
32500 mg/kg/13W-I
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - aggression Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
45 gm/kg/90D-I
TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of endocrine pancreas Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
14 gm/kg/28D-I
TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of endocrine pancreas Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
1260 mg/kg/28D-I
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - fibrosis, focal (pneumoconiosis) Liver - changes in liver weight Endocrine - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
1300 mg/kg/13D-I
TOXIC EFFECTS :
Liver - changes in liver weight Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
91875 mg/kg/2Y-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Endocrine - thyroid tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
800 ug/kg/W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Skin and Appendages - tumors Tumorigenic - tumors at site of application
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
800 ug/kg/W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - tumors at site of application
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
110 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
125 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
70 mg/kg
SEX/DURATION :
female 9-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - skin and skin appendages
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
62500 ug/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
40 mg/kg
SEX/DURATION :
female 3-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
145 mg/kg
SEX/DURATION :
female 15-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1100 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
195 mg/kg
SEX/DURATION :
female 5-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
140 ug/kg
SEX/DURATION :
female 15-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Maternal Effects - other effects Reproductive - Effects on Newborn - stillbirth
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
90 mg/kg
SEX/DURATION :
female 10-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
200 mg/kg
SEX/DURATION :
female 1-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
30 mg/kg
SEX/DURATION :
female 10-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1 gm/kg
SEX/DURATION :
female 1-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
100 mg/kg
SEX/DURATION :
male 10 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
50 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - hepatobiliary system Reproductive - Effects on Newborn - other postnatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
male 8 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
300 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
350 mg/kg
SEX/DURATION :
female 20-21 day(s) after conception lactating female 5 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
50 mg/kg
SEX/DURATION :
female 20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Inhalation
DOSE :
900 ug/kg/4M
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 10-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
100 mg/kg
SEX/DURATION :
female 8-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
100 mg/kg
SEX/DURATION :
female 10-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
105 mg/kg
SEX/DURATION :
female 21 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - oogenesis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
4500 ug/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
400 mg/kg
SEX/DURATION :
female 6-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
10 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
150 mg/kg
SEX/DURATION :
female 8-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
100 mg/kg
SEX/DURATION :
female 10-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
396 mg/kg
SEX/DURATION :
female 1-23 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
648 mg/kg
SEX/DURATION :
female 1-23 week(s) after conception lactating female 15 week(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
388 mg/kg
SEX/DURATION :
female 1-22 week(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
19500 ug/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
19500 ug/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
1250 ug/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
100 mg/kg
SEX/DURATION :
female 7-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
female 7-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
Mutation test systems - not otherwise specified
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sperm Morphology

MUTATION DATA

TEST SYSTEM :
Rodent - hamster
DOSE/DURATION :
1 gm/kg
REFERENCE :
EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945- Volume(issue)/page/year: 34,1205,1978 *** REVIEWS *** TOXICOLOGY REVIEW PEDIAU Pediatrics. (American Academy of Pediatrics, P.O. Box 1034, Evanston, IL 60204) V.1- 1948- Volume(issue)/page/year: 56,134,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5841 No. of Facilities: 25 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 1358 (estimated) No. of Female Employees: 956 (estimated)

卓那比醇 MSDS

模块 1. 化学品
  1.1 产品标识符
    : Δ9-四氢大麻酚 溶液
    产品名称
  1.2 鉴别的其他方法
    无数据资料
  1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
    仅用于研发。不作为药品、家庭或其它用途。
模块 2. 危险性概述
  2.1 GHS-分类
    易燃液体 (类别 2)
    皮肤刺激 (类别 2)
    眼睛刺激 (类别 2B)
    特异性靶器官系统毒性（一次接触） (类别 3)
  2.2 GHS 标记要素，包括预防性的陈述
    象形图
    警示词        危险    
    危险申明
    H225        高度易燃液体和蒸气    
    H315        造成皮肤刺激。    
    H320        造成眼刺激。    
    H335        可能引起呼吸道刺激。    
    警告申明
    预防措施
    P210        远离热源、火花、明火和热表面。- 禁止吸烟。    
    P233        保持容器密闭。    
    P240        容器和接收设备接地。    
    P241        使用防爆的电气/ 通风/ 照明 设备。    
    P242        只能使用不产生火花的工具。    
    P243        采取措施，防止静电放电。    
    P261        避免吸入粉尘/烟/气体/烟雾/蒸气/喷雾.    
    P264        操作后彻底清洁皮肤。    
    P271        只能在室外或通风良好之处使用。    
    P280        戴防护手套/穿防护服/戴护目镜/戴面罩.    
    事故响应
    P303 + P361 + P353        如果皮肤(或头发)接触：立即除去/脱掉所有沾污的衣物，用水清洗皮肤/淋    
    浴。
    P304 + P340        如吸入: 将患者移到新鲜空气处休息，并保持呼吸舒畅的姿势。    
    P305 + P351 + P338        如与眼睛接触，用水缓慢温和地冲洗几分钟。如戴隐形眼镜并可方便地取    
    出，取出隐形眼镜，然后继续冲洗.
    P312        如感觉不适，呼救中毒控制中心或医生.    
    P321        具体处置（见本标签上提供的急救指导）。    
    P332 + P313        如觉皮肤刺激：求医/就诊。    
    P337 + P313        如仍觉眼睛刺激：求医/就诊。    
    P362        脱掉沾污的衣服，清洗后方可再用。    
    P370 + P378        火灾时： 用干的砂子，干的化学品或耐醇性的泡沫来灭火。    
    安全储存
    P403 + P233        存放于通风良的地方。 保持容器密闭。    
    P403 + P235        保持低温，存放于通风良好处。    
    P405        存放处须加锁。    
    废弃处置
    P501        将内容物/ 容器处理到得到批准的废物处理厂。    
  2.3 其它危害物 - 无
模块 3. 成分/组成信息
  3.2 混合物
    : C21H30O2
    分子式
    : 314.46 g/mol
    分子量
    组分        分类        浓度或浓度范围    
    Ethanol
    50 - 100 %
    化学文摘登记号(CA 64-17-5        Flam. Liq. 2; Eye Irrit. 2B;    
    S No.)        200-578-6        H225, H320    
    EC-编号        603-002-00-5    
    索引编号
    1-Trans-delta9-tetrahydrocannabinol
    化学文摘登记号(CA 1972-08-3        Acute Tox. 4; Repr. 2; Aquatic 1 - 3 %    
    S No.)        Chronic 4; H302, H361, H413    
    如需在本章节中提及的H类告知和R类描述的全部文字说明,请见第16章节.
模块 4. 急救措施
  4.1 必要的急救措施描述
    一般的建议
    请教医生。 向到现场的医生出示此安全技术说明书。
    吸入
    如果吸入,请将患者移到新鲜空气处。 如呼吸停止,进行人工呼吸。 请教医生。
    皮肤接触
    用肥皂和大量的水冲洗。 请教医生。
    眼睛接触
    用大量水彻底冲洗至少15分钟并请教医生。
    食入
    禁止催吐。 切勿给失去知觉者通过口喂任何东西。 用水漱口。 请教医生。
  4.2 主要症状和影响，急性和迟发效应
    延长或重复暴露可能引起：, 中枢神经系统抑制, 对心脏有害, 恶心, 呕吐, 头痛,
    据我们所知，此化学，物理和毒性性质尚未经完整的研究。
  4.3 及时的医疗处理和所需的特殊处理的说明和指示
    无数据资料
模块 5. 消防措施
  5.1 灭火介质
    灭火方法及灭火剂
    用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。
  5.2 源于此物质或混合物的特别的危害
    碳氧化物
  5.3 给消防员的建议
    如必要的话,戴自给式呼吸器去救火。
  5.4 进一步信息
    用水喷雾冷却未打开的容器。
模块 6. 泄露应急处理
  6.1 作业人员防护措施、防护装备和应急处置程序
    使用个人防护用品。 避免吸入蒸气、烟雾或气体。 保证充分的通风。 移去所有火源。
    人员疏散到安全区域。 谨防蒸气积累达到可爆炸的浓度。蒸气能在低洼处积聚。
  6.2 环境保护措施
    如能确保安全，可采取措施防止进一步的泄漏或溢出。 不要让产品进入下水道。
  6.3 泄漏化学品的收容、清除方法及所使用的处置材料
    围堵溢出，用防电真空清洁器或湿刷子将溢出物收集起来，并放置到容器中去,根据当地规定处理(见第13部
    分)。
  6.4 参考其他部分
    丢弃处理请参阅第13节。
模块 7. 操作处置与储存
  7.1 安全操作的注意事项
    避免接触皮肤和眼睛。 避免吸入蒸气和烟雾。
    切勿靠近火源。－严禁烟火。采取措施防止静电积聚。
  7.2 安全储存的条件,包括任何不兼容性
    贮存在阴凉处。 使容器保持密闭，储存在干燥通风处。
    打开了的容器必须仔细重新封口并保持竖放位置以防止泄漏。
    建议的贮存温度： -20 °C
  7.3 特定用途
    无数据资料
模块 8. 接触控制和个体防护
  8.1 容许浓度
    最高容许浓度
  8.2 暴露控制
    适当的技术控制
    根据良好的工业卫生和安全规范进行操作。 休息前和工作结束时洗手。
    个体防护设备
    眼/面保护
    面罩與安全眼鏡请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟) 检测与批准的设备防护眼部。
    皮肤保护
    戴手套取 手套在使用前必须受检查。
    请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
    使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
    所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
    身体保护
    防渗透的衣服, 阻燃防静电防护服,
    防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
    呼吸系统防护
    如危险性评测显示需要使用空气净化的防毒面具，请使用全面罩式多功能防毒面具（US）或ABEK型
    （EN
    14387）防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式，则使用全面罩式送风防
    毒面具。 呼吸器使用经过测试并通过政府标准如NIOSH（US）或CEN（EU）的呼吸器和零件。
模块 9. 理化特性
  9.1 基本的理化特性的信息
    a) 外观与性状
    形状: 液体
    b) 气味
    无数据资料
    c) 气味阈值
    无数据资料
    d) pH值
    无数据资料
    e) 熔点/凝固点
    无数据资料
    f) 沸点、初沸点和沸程
    无数据资料
    g) 闪点
    无数据资料
    h) 蒸发速率
    无数据资料
    i) 易燃性(固体,气体)
    无数据资料
    j) 高的/低的燃烧性或爆炸性限度 无数据资料
    k) 蒸气压
    无数据资料
    l) 蒸汽密度
    无数据资料
    m) 密度/相对密度
    无数据资料
    n) 水溶性
    无数据资料
    o) n-辛醇/水分配系数
    无数据资料
    p) 自燃温度
    无数据资料
    q) 分解温度
    无数据资料
    r) 粘度
    无数据资料
模块 10. 稳定性和反应活性
  10.1 反应性
    无数据资料
  10.2 稳定性
    无数据资料
  10.3 危险反应
    无数据资料
  10.4 应避免的条件
    热,火焰和火花。 极端温度和直接日晒。
  10.5 不相容的物质
    无数据资料
  10.6 危险的分解产物
    其它分解产物 - 无数据资料
模块 11. 毒理学资料
  11.1 毒理学影响的信息
    急性毒性
    无数据资料
    皮肤刺激或腐蚀
    无数据资料
    眼睛刺激或腐蚀
    无数据资料
    呼吸道或皮肤过敏
    无数据资料
    生殖细胞致突变性
    无数据资料
    致癌性
    IARC:
    此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。
    生殖毒性
    无数据资料
    特异性靶器官系统毒性（一次接触）
    无数据资料
    特异性靶器官系统毒性（反复接触）
    无数据资料
    吸入危险
    无数据资料
    潜在的健康影响
    吸入        吸入可能有害。 引起呼吸道刺激。    
    摄入        如服入是有害的。    
    皮肤        通过皮肤吸收可能有害。 造成皮肤刺激。    
    眼睛        引起眼睛刺激。    
    接触后的征兆和症状
    延长或重复暴露可能引起：, 中枢神经系统抑制, 对心脏有害, 恶心, 呕吐, 头痛,
    据我们所知，此化学，物理和毒性性质尚未经完整的研究。
    附加说明
    化学物质毒性作用登记: 无数据资料
模块 12. 生态学资料
  12.1 生态毒性
    无数据资料
  12.2 持久性和降解性
    无数据资料
  12.3 潜在的生物累积性
    无数据资料
  12.4 土壤中的迁移性
    无数据资料
  12.5 PBT 和 vPvB的结果评价
    无数据资料
  12.6 其它不良影响
    无数据资料
模块 13. 废弃处置
  13.1 废物处理方法
    产品
    在装备有加力燃烧室和洗刷设备的化学焚烧炉内燃烧处理,特别在点燃的时候要注意,因为此物质是高度易燃
    性物质 将剩余的和不可回收的溶液交给有许可证的公司处理。
    受污染的容器和包装
    按未用产品处置。
模块 14. 运输信息
  14.1 联合国危险货物编号
    欧洲陆运危规: 1170        国际海运危规: 1170        国际空运危规: 1170    
  14.2 联合国运输名称
    欧洲陆运危规: ETHANOL SOLUTION
    国际海运危规: ETHANOL SOLUTION
    国际空运危规: Ethanol solution
  14.3 运输危险类别
    欧洲陆运危规: 3        国际海运危规: 3        国际空运危规: 3    
  14.4 包裹组
    欧洲陆运危规: II        国际海运危规: II        国际空运危规: II    
  14.5 环境危险
    欧洲陆运危规: 否        国际海运危规        国际空运危规: 否    
    海洋污染物（是/否）: 否
  14.6 对使用者的特别提醒
    无数据资料

模块 15 - 法规信息
N/A

模块16 - 其他信息
N/A

卓那比醇 分子结构与计算化学数据

分子结构数据

1、摩尔折射率：95.49

2、摩尔体积（cm3/mol）：309.7

3、等张比容（90.2K）：753.7

4、表面张力（dyne/cm）：35

5、介电常数：无可用的

6、极化率：37.85

7、单一同位素质量：314.22458 Da

8、标称质量：314 Da

9、平均质量：314.4617 Da

计算化学数据

1、疏水参数计算参考值（XlogP）：7

2、氢键供体数量：1

3、氢键受体数量：2

4、可旋转化学键数量：4

5、互变异构体数量：9

6、拓扑分子极性表面积（TPSA）：29.5

7、重原子数量：23

8、表面电荷：0

9、复杂度：439

10、同位素原子数量：0

11、确定原子立构中心数量：2

12、不确定原子立构中心数量：0

13、确定化学键立构中心数量：0

14、不确定化学键立构中心数量：0

15、共价键单元数量：1

卓那比醇 下游产品

DEA限制

推荐供应商更多供应商>>

@2009-2024 洛克化工网 浙ICP备16009103号 版权声明